INOVIO wins $80M judgment against VGXI and GeneOne for contract breach in DNA plasmid manufacturing case

INOVIO Pharmaceuticals secured a court judgment awarding $80.4 million against VGXI and GeneOne for breaching a supply agreement related to DNA plasmid manufacturing. The court granted $61.75 million in compensatory damages and $18.67 million in fees and costs. Despite the win, INOVIO warns the defendants' financial troubles may limit recovery of the full amount. The company plans to pursue all reasonable efforts to collect the awarded damages.

As of Oct 21, 2026 03:12 WIB, INOVIO Pharmaceuticals (INO) trades at USD 1.18 on Pluang, up 17.50% in one day but still well below its 52-week high of USD 2.60. Despite the recent legal win, the stock remains closer to its 52-week low of USD 0.66, reflecting ongoing market caution. Pluang data also shows a full 100% sell order activity, indicating investors are currently offloading shares despite the positive judgment.